Presenter Disclosure Information Jochen Senges The following relationships exist related to this presentation: Speaker CompensationTrommsdorff ArzneimittelModest.
DAIDS Safety Workshop: Part III Expedited Reporting via DAERS Albert Yoyin, M.D. and Archita Chatterjee, M.S. DAIDS RSC Safety Office Johannesburg, South.
Phase-III Studie: HECTOR Topotecan plus Carboplatin (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin) -Intergroup Study of NOGGO und Studiengruppe.
Switch ABC/3TC to TDF/FTC SWIFT Study. SWIFT Study: Switch ABC/3TC to TDF/FTC Design Campo R, CID 2013, Jan 29 (epub ahead of print) LPV/rATV/rFPV.
Adapted from the PMB through CTEP 2008 (revised 09/2014) NCORP-KC Guidelines for Investigational Drug Management.
1 SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) R Campo 1, E DeJesus 2, H Khanlou 3, H Wang 4, K White.
ClinicalTrials.gov Results Reporting from the Ground Up [Presenter Name and contact Info] 1.
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca Heart Failure (GISSI-HF) trial GISSI-HF Adapted from: Tavazzi et al.
The Good, The Bad and The Ugly of Clinical Research Sites.
Cora Lee Wetherington, Ph.D. Women & Gender Research Coordinator National Institute on Drug Abuse Women Across the Life Span Conference July 12-13, 2004.
Presentation Corex - ACTO, Moscow, 03 October 2012 Volkov Denis.